Primary CNS Lymphoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.
Conditions: Cerebral Lymphoma Interventions: Diagnostic Test: MRI imaging; Diagnostic Test: Cerebral biopsy Sponsors: IRCCS San Raffaele Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Conditions: Primary Central Nervous System Lymphoma Interventions: Procedure: Cognitive Assessment; Biological: Obinutuzumab; Other: Quality of Life Assessment Sponsors: Providence Health& Services Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 18, 2023 Category: Research Source Type: clinical trials
A Retrospective Study of Newly-diagnosed PCNSL Treated With a Methotrexate (MTX) and Orelabrutinib-based Regimen
Conditions: Primary Central Nervous System Lymphoma Interventions: Drug: Orelabrutinib Sponsors: Huashan Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
Condition: Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma Intervention: Drug: thiotepa combined with pomalidomide Sponsor: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study
Condition: Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma Intervention: Radiation: intensity-modulated radiotherapy (IMRT) Sponsor: National Taiwan University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 13, 2023 Category: Research Source Type: clinical trials
